Work

A first-in-human phase I study of VGX-100, a selective anti-VEGF-C antibody, alone and in combination with bevacizumab in patients with advanced solid tumors.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.2524

Authors: Gerald Steven Falchook, Jonathan Wade Goldman, Jayesh Desai, Ian Leitch, David S. Hong, Vivek Subbiah, Razelle Kurzrock, Lee S. Rosen

Institutions: The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, The Royal Melbourne Hospital, University of California San Diego

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2802922348

Cites:

Cited by: 21

Related to: 10